Literature DB >> 30944926

A deep learning model based on sparse auto-encoder for prioritizing cancer-related genes and drug target combinations.

Ji-Wei Chang1,2, Yuduan Ding1,2, Muhammad Tahir Ul Qamar1,2, Yin Shen1, Junxiang Gao1, Ling-Ling Chen1,2.   

Abstract

Prioritization of cancer-related genes from gene expression profiles and proteomic data is vital to improve the targeted therapies research. Although computational approaches have been complementing high-throughput biological experiments on the understanding of human diseases, it still remains a big challenge to accurately discover cancer-related proteins/genes via automatic learning from large-scale protein/gene expression data and protein-protein interaction data. Most of the existing methods are based on network construction combined with gene expression profiles, which ignore the diversity between normal samples and disease cell lines. In this study, we introduced a deep learning model based on a sparse auto-encoder to learn the specific characteristics of protein interactions in cancer cell lines integrated with protein expression data. The model showed learning ability to identify cancer-related proteins/genes from the input of different protein expression profiles by extracting the characteristics of protein interaction information, which could also predict cancer-related protein combinations. Comparing with other reported methods including differential expression and network-based methods, our model got the highest area under the curve value (>0.8) in predicting cancer-related genes. Our study prioritized ~500 high-confidence cancer-related genes; among these genes, 211 already known cancer drug targets were found, which supported the accuracy of our method. The above results indicated that the proposed auto-encoder model could computationally prioritize candidate proteins/genes involved in cancer and improve the targeted therapies research.
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Year:  2019        PMID: 30944926     DOI: 10.1093/carcin/bgz044

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  6 in total

1.  Integrated computational approaches to screen gene expression data to determine key genes and therapeutic targets for type-2 diabetes mellitus.

Authors:  Fahad A Alhumaydhi
Journal:  Saudi J Biol Sci       Date:  2022-02-10       Impact factor: 4.052

2.  A Comprehensive Computational Screening of Phytochemicals Derived from Saudi Medicinal Plants against Human CC Chemokine Receptor 7 to Identify Potential Anti-Cancer Therapeutics.

Authors:  Faris Alrumaihi
Journal:  Molecules       Date:  2021-10-21       Impact factor: 4.411

Review 3.  Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence.

Authors:  Nahlah Makki Almansour
Journal:  Front Mol Biosci       Date:  2022-01-25

4.  Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer.

Authors:  Anna Gogleva; Dimitris Polychronopoulos; Matthias Pfeifer; Vladimir Poroshin; Michaël Ughetto; Matthew J Martin; Hannah Thorpe; Aurelie Bornot; Paul D Smith; Ben Sidders; Jonathan R Dry; Miika Ahdesmäki; Ultan McDermott; Eliseo Papa; Krishna C Bulusu
Journal:  Nat Commun       Date:  2022-03-29       Impact factor: 14.919

5.  Metadata analysis to explore hub of the hub-genes highlighting their functions, pathways and regulators for cervical cancer diagnosis and therapies.

Authors:  Md Selim Reza; Md Alim Hossen; Md Harun-Or-Roshid; Mst Ayesha Siddika; Md Hadiul Kabir; Md Nurul Haque Mollah
Journal:  Discov Oncol       Date:  2022-08-22

Review 6.  Quantitative proteomics characterization of cancer biomarkers and treatment.

Authors:  Xiao-Li Yang; Yi Shi; Dan-Dan Zhang; Rui Xin; Jing Deng; Ting-Miao Wu; Hui-Min Wang; Pei-Yao Wang; Ji-Bin Liu; Wen Li; Yu-Shui Ma; Da Fu
Journal:  Mol Ther Oncolytics       Date:  2021-04-20       Impact factor: 7.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.